EIT Pharma Presents Extended Phase 3 D-LIVR Trial Analyses at AASLD's The Liver Meeting® 2026

EIT Pharma presented extended analyses from its phase 3 D-LIVR trial of lonafarnib-based treatment for chronic hepatitis D at the American Association for the Study of Liver Diseases’ Liver Meeting in Denver. The study included more than 400 participants across 21 countries. The company said the analyses showed benefits persisting after treatment ended and supported further development of a finite treatment regimen.